In conclusion, we have shown that CytoSorb treatment, used in patients with SIRS of different etiologies, is associated with a decrease in IL-6 and a corresponding beneficial effect on hemodynamics and possibly also survival. This evidence concerns the gene IL6 and systemic inflammatory response syndrome.